Abstract
Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.
| Original language | English |
|---|---|
| Pages (from-to) | 3221-3227 |
| Number of pages | 7 |
| Journal | FEBS Letters |
| Volume | 589 |
| Issue number | 21 |
| Early online date | 2 Oct 2015 |
| DOIs | |
| Publication status | Published - 24 Oct 2015 |
Fingerprint
Cite this
}
Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance : evidence and mechanisms. / Lipina, Christopher; Hundal, Harinder S. (Lead / Corresponding author).
In: FEBS Letters, Vol. 589, No. 21, 24.10.2015, p. 3221-3227.Research output: Contribution to journal › Article
TY - JOUR
T1 - Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance
T2 - evidence and mechanisms
AU - Lipina, Christopher
AU - Hundal, Harinder S.
N1 - Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
PY - 2015/10/24
Y1 - 2015/10/24
N2 - Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.
AB - Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.
U2 - 10.1016/j.febslet.2015.09.018
DO - 10.1016/j.febslet.2015.09.018
M3 - Article
C2 - 26434718
VL - 589
SP - 3221
EP - 3227
JO - FEBS Letters
JF - FEBS Letters
SN - 0014-5793
IS - 21
ER -